Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies

Marc C. Pulanco; Anne T. Madsen; Ankit Tanwar; Devin T. Corrigan; Xingxing Zang

doi:10.1038/s41423-023-01019-8

Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies

Marc C. Pulanco, Anne T. Madsen, Ankit Tanwar, Devin T. Corrigan, Xingxing Zang

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

The B7/CD28 families of immune checkpoints play vital roles in negatively or positively regulating immune cells in homeostasis and various diseases. Recent basic and clinical studies have revealed novel biology of the B7/CD28 families and new therapeutics for cancer therapy. In this review, we discuss the newly discovered KIR3DL3/TMIGD2/HHLA2 pathways, PD-1/PD-L1 and B7-H3 as metabolic regulators, the glycobiology of PD-1/PD-L1, B7x (B7-H4) and B7-H3, and the recently characterized PD-L1/B7-1 cis-interaction. We also cover the tumor-intrinsic and -extrinsic resistance mechanisms to current anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapies in clinical settings. Finally, we review new immunotherapies targeting B7-H3, B7x, PD-1/PD-L1, and CTLA-4 in current clinical trials.

Original language	English (US)
Pages (from-to)	694-713
Number of pages	20
Journal	Cellular and Molecular Immunology
Volume	20
Issue number	7
DOIs	https://doi.org/10.1038/s41423-023-01019-8
State	Published - Jul 2023

Keywords

B7 family
glycobiology
immune checkpoints
metabolic regulators
therapy resistance

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41423-023-01019-8

Cite this

@article{2b09ac1f1d4641748f884a330dfb917b,

title = "Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies",

abstract = "The B7/CD28 families of immune checkpoints play vital roles in negatively or positively regulating immune cells in homeostasis and various diseases. Recent basic and clinical studies have revealed novel biology of the B7/CD28 families and new therapeutics for cancer therapy. In this review, we discuss the newly discovered KIR3DL3/TMIGD2/HHLA2 pathways, PD-1/PD-L1 and B7-H3 as metabolic regulators, the glycobiology of PD-1/PD-L1, B7x (B7-H4) and B7-H3, and the recently characterized PD-L1/B7-1 cis-interaction. We also cover the tumor-intrinsic and -extrinsic resistance mechanisms to current anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapies in clinical settings. Finally, we review new immunotherapies targeting B7-H3, B7x, PD-1/PD-L1, and CTLA-4 in current clinical trials.",

keywords = "B7 family, glycobiology, immune checkpoints, metabolic regulators, therapy resistance",

author = "Pulanco, {Marc C.} and Madsen, {Anne T.} and Ankit Tanwar and Corrigan, {Devin T.} and Xingxing Zang",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to CSI and USTC.",

year = "2023",

month = jul,

doi = "10.1038/s41423-023-01019-8",

language = "English (US)",

volume = "20",

pages = "694--713",

journal = "Cellular and Molecular Immunology",

issn = "1672-7681",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Recent advancements in the B7/CD28 immune checkpoint families

T2 - new biology and clinical therapeutic strategies

AU - Pulanco, Marc C.

AU - Madsen, Anne T.

AU - Tanwar, Ankit

AU - Corrigan, Devin T.

AU - Zang, Xingxing

PY - 2023/7

Y1 - 2023/7

N2 - The B7/CD28 families of immune checkpoints play vital roles in negatively or positively regulating immune cells in homeostasis and various diseases. Recent basic and clinical studies have revealed novel biology of the B7/CD28 families and new therapeutics for cancer therapy. In this review, we discuss the newly discovered KIR3DL3/TMIGD2/HHLA2 pathways, PD-1/PD-L1 and B7-H3 as metabolic regulators, the glycobiology of PD-1/PD-L1, B7x (B7-H4) and B7-H3, and the recently characterized PD-L1/B7-1 cis-interaction. We also cover the tumor-intrinsic and -extrinsic resistance mechanisms to current anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapies in clinical settings. Finally, we review new immunotherapies targeting B7-H3, B7x, PD-1/PD-L1, and CTLA-4 in current clinical trials.

AB - The B7/CD28 families of immune checkpoints play vital roles in negatively or positively regulating immune cells in homeostasis and various diseases. Recent basic and clinical studies have revealed novel biology of the B7/CD28 families and new therapeutics for cancer therapy. In this review, we discuss the newly discovered KIR3DL3/TMIGD2/HHLA2 pathways, PD-1/PD-L1 and B7-H3 as metabolic regulators, the glycobiology of PD-1/PD-L1, B7x (B7-H4) and B7-H3, and the recently characterized PD-L1/B7-1 cis-interaction. We also cover the tumor-intrinsic and -extrinsic resistance mechanisms to current anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapies in clinical settings. Finally, we review new immunotherapies targeting B7-H3, B7x, PD-1/PD-L1, and CTLA-4 in current clinical trials.

KW - B7 family

KW - glycobiology

KW - immune checkpoints

KW - metabolic regulators

KW - therapy resistance

UR - http://www.scopus.com/inward/record.url?scp=85153107037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85153107037&partnerID=8YFLogxK

U2 - 10.1038/s41423-023-01019-8

DO - 10.1038/s41423-023-01019-8

M3 - Review article

C2 - 37069229

AN - SCOPUS:85153107037

SN - 1672-7681

VL - 20

SP - 694

EP - 713

JO - Cellular and Molecular Immunology

JF - Cellular and Molecular Immunology

IS - 7

ER -

Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this